Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis

Int J Cardiol. 2014 Oct 20;176(3):1113-5. doi: 10.1016/j.ijcard.2014.07.106. Epub 2014 Aug 1.
No abstract available

Keywords: Atrial natriuretic peptide; Biomarkers; Light-chain amyloidosis; N-terminal brain-type natriuretic peptide; Survival; Troponin T.

Publication types

  • Comparative Study
  • Evaluation Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloidosis / blood*
  • Amyloidosis / diagnosis*
  • Atrial Natriuretic Factor / blood*
  • Biomarkers / blood
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin kappa-Chains / blood*
  • Immunoglobulin lambda-Chains / blood*
  • Middle Aged
  • Natriuretic Peptide, Brain / blood*
  • Peptide Fragments / blood*
  • Risk Factors

Substances

  • Biomarkers
  • Immunoglobulin kappa-Chains
  • Immunoglobulin lambda-Chains
  • Peptide Fragments
  • midregional pro-atrial natriuretic peptide, human
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Atrial Natriuretic Factor